Adamas Pharmaceuticals 주식 주식분석 | 주식가격 | 뉴스 | ADMS | US00548A1060 | A111X7

날짜	Adamas Pharmaceuticals 주식 가격
	8.22 undefined
	8.16 undefined

날짜	Adamas Pharmaceuticals 매출	Adamas Pharmaceuticals EBIT	Adamas Pharmaceuticals 이익
2025e	195.68 백만 undefined	0 undefined	-12.58 백만 undefined
2024e	162.49 백만 undefined	0 undefined	-7.96 백만 undefined
2023e	137.63 백만 undefined	0 undefined	-5.14 백만 undefined
2022e	128.21 백만 undefined	0 undefined	-10.54 백만 undefined
2021e	96.04 백만 undefined	0 undefined	-29.94 백만 undefined
2020	74.46 백만 undefined	-44.16 백만 undefined	-57.4 백만 undefined
2019	54.64 백만 undefined	-92.24 백만 undefined	-105.19 백만 undefined
2018	34.05 백만 undefined	-115.02 백만 undefined	-131 백만 undefined
2017	570,000 undefined	-87.93 백만 undefined	-89.49 백만 undefined
2016	570,000 undefined	-60.98 백만 undefined	-60.06 백만 undefined
2015	1.92 백만 undefined	-57.44 백만 undefined	-51.8 백만 undefined
2014	55.85 백만 undefined	18.51 백만 undefined	10.22 백만 undefined
2013	71.1 백만 undefined	57.02 백만 undefined	50.92 백만 undefined
2012	37.47 백만 undefined	19.95 백만 undefined	17.74 백만 undefined
2011	1.98 백만 undefined	-8.06 백만 undefined	-8.24 백만 undefined

	매출	EBIT	이익
2011	1.98 백만 USD	-8.06 백만 USD	-8.24 백만 USD
2012	37.47 백만 USD	19.95 백만 USD	17.74 백만 USD
2013	71.1 백만 USD	57.02 백만 USD	50.92 백만 USD
2014	55.85 백만 USD	18.51 백만 USD	10.22 백만 USD
2015	1.92 백만 USD	-57.44 백만 USD	-51.8 백만 USD
2016	570,000 USD	-60.98 백만 USD	-60.06 백만 USD
2017	570,000 USD	-87.93 백만 USD	-89.49 백만 USD
2018	34.05 백만 USD	-115.02 백만 USD	-131 백만 USD
2019	54.64 백만 USD	-92.24 백만 USD	-105.19 백만 USD
2020	74.46 백만 USD	-44.16 백만 USD	-57.4 백만 USD
2021e	96.04 백만 USD	0 USD	-29.94 백만 USD
2022e	128.21 백만 USD	0 USD	-10.54 백만 USD
2023e	137.63 백만 USD	0 USD	-5.14 백만 USD
2024e	162.49 백만 USD	0 USD	-7.96 백만 USD
2025e	195.68 백만 USD	0 USD	-12.58 백만 USD

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021e	2022e	2023e	2024e	2025e
1	37	71	55	1	0	0	34	54	74	96	128	137	162	195
-	3,600.00	91.89	-22.54	-98.18	-	-	-	58.82	37.04	29.73	33.33	7.03	18.25	20.37
-	-	-	-	-	-	-	97.06	96.30	97.30	-	-	-	-	-
0	0	0	0	0	0	0	33	52	72	0	0	0	0	0
-8	19	57	18	-57	-60	-87	-115	-92	-44	0	0	0	0	0
-800.00	51.35	80.28	32.73	-5,700.00	-	-	-338.24	-170.37	-59.46	-	-	-	-	-
-8	17	50	10	-51	-60	-89	-131	-105	-57	-29	-10	-5	-7	-12
-	-312.50	194.12	-80.00	-610.00	17.65	48.33	47.19	-19.85	-45.71	-49.12	-65.52	-50.00	40.00	71.43
16.43	16.43	16.43	17.11	18.11	21.71	22.56	26.89	27.68	28.31	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020

3.1	63	85.6	122.4	106.8	113.7	173.4	210.9	132.6	83.4
0.4	0.9	0.1	0.5	1.3	0.8	0.4	5.5	5.8	8
0.1	0	0	0	4.3	0.2	1	0.9	1.2	1.3
0	0	0	0	0	0	1.7	5.1	5.3	7.3
0.3	0.3	0.2	0.6	0.8	2.4	2.6	6.1	5.4	11.8
3.9	64.2	85.9	123.5	113.2	117.1	179.1	228.5	150.3	111.8
0.1	0.1	0.2	1.2	2.4	3.2	3.1	3.7	10.5	8.3
0	0	0	36.4	13.2	22.3	3	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0.1	0	0	0.9	2.8	1.3	0
0.1	0.1	0.2	37.7	15.6	25.5	7	6.5	11.8	8.3
4	64.3	86.1	161.2	128.8	142.6	186.1	235	162.1	120.1

15.3	19.1	19.1	0	0	0	0	0	0	0
75.6	76.4	77.2	157.6	178.5	254.6	278	432.8	446.9	455.3
-89.2	-71.5	-20.6	-10.3	-62.2	-122.2	-211.7	-342.7	-447.9	-505.3
0	0	0	-0.2	-0.2	-0.2	-0.2	-0.3	0	0
0	0	0	0	0	0	0	0	0	0
1.7	24	75.7	147.1	116.1	132.2	66.1	89.8	-1	-50
1.5	3.3	2.1	3.7	3.1	3.6	3.9	6.6	6.9	2.1
0.7	1	1.8	3.8	8.4	5.8	12.4	15.5	17.8	29
0.1	30.3	0.3	5.1	0.4	0.3	0.3	0.5	0.2	0
0	4	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1.7	2	3.7
2.3	38.6	4.2	12.6	11.9	9.7	16.6	24.3	26.9	34.8
0	0	0	0	0	0	102.6	117.5	125.7	126.3
0	0	0	0	0	0	0	0	0	0
0.1	1.7	6.2	1.6	0.7	0.5	0.8	3.2	10.4	8.8
0.1	1.7	6.2	1.6	0.7	0.5	103.4	120.7	136.1	135.1
2.4	40.3	10.4	14.2	12.6	10.2	120	145	163	169.9
4.1	64.3	86.1	161.3	128.7	142.4	186.1	234.8	162	119.9

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
-8	17	50	10	-51	-60	-89	-131	-105	-57
0	0	0	0	0	0	1,000	1,000	1,000	0
0	0	0	0	0	0	0	0	0	0
1	31	-29	10	-6	0	3	-9	-5	-15
0	2	5	6	10	10	18	35	28	21
0	0	0	0	0	0	0	2	6	11
0	0	1	0	4	0	0	0	0	0
-6	51	26	27	-47	-48	-66	-104	-80	-50
0	0	0	-1	-1	-1	-1	-1	0	0
0	0	0	-97	8	-26	25	-69	88	54
0	0	0	-96	9	-25	26	-68	88	54
0	0	0	0	0	0	0	0	0	0
1	3	-4	0	0	0	99	0	0	0
6	3	0	45	10	65	9	138	1	1
8	7	-3	45	10	65	108	138	1	1
-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0
1	59	22	-24	-28	-9	67	-34	9	5
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0

Adamas Pharmaceuticals 브루토마진	Adamas Pharmaceuticals 이익 마진	Adamas Pharmaceuticals EBIT-마진	Adamas Pharmaceuticals 이익 마진
2025e	97.26 %	0 %	-6.43 %
2024e	97.26 %	0 %	-4.9 %
2023e	97.26 %	0 %	-3.74 %
2022e	97.26 %	0 %	-8.22 %
2021e	97.26 %	0 %	-31.17 %
2020	97.26 %	-59.31 %	-77.09 %
2019	95.48 %	-168.81 %	-192.51 %
2018	98.12 %	-337.8 %	-384.73 %
2017	96.49 %	-15,426.31 %	-15,700 %
2016	97.26 %	-10,698.25 %	-10,536.84 %
2015	97.26 %	-2,991.67 %	-2,697.92 %
2014	97.26 %	33.14 %	18.3 %
2013	97.26 %	80.2 %	71.62 %
2012	97.26 %	53.24 %	47.34 %
2011	97.26 %	-407.07 %	-416.16 %

	브루토마진	EBIT-마진	이익 마진
2011	97.26 %	-407.07 %	-416.16 %
2012	97.26 %	53.24 %	47.34 %
2013	97.26 %	80.2 %	71.62 %
2014	97.26 %	33.14 %	18.3 %
2015	97.26 %	-2,991.67 %	-2,697.92 %
2016	97.26 %	-10,698.25 %	-10,536.84 %
2017	96.49 %	-15,426.31 %	-15,700 %
2018	98.12 %	-337.8 %	-384.73 %
2019	95.48 %	-168.81 %	-192.51 %
2020	97.26 %	-59.31 %	-77.09 %
2021e	97.26 %	0 %	-31.17 %
2022e	97.26 %	0 %	-8.22 %
2023e	97.26 %	0 %	-3.74 %
2024e	97.26 %	0 %	-4.9 %
2025e	97.26 %	0 %	-6.43 %

날짜	Adamas Pharmaceuticals 주당 매출	Adamas Pharmaceuticals EBIT 당 주식	Adamas Pharmaceuticals 주당 이익
2025e	6.78 undefined	0 undefined	-0.44 undefined
2024e	5.63 undefined	0 undefined	-0.28 undefined
2023e	4.77 undefined	0 undefined	-0.18 undefined
2022e	4.44 undefined	0 undefined	-0.36 undefined
2021e	3.33 undefined	0 undefined	-1.04 undefined
2020	2.63 undefined	-1.56 undefined	-2.03 undefined
2019	1.97 undefined	-3.33 undefined	-3.8 undefined
2018	1.27 undefined	-4.28 undefined	-4.87 undefined
2017	0.03 undefined	-3.9 undefined	-3.97 undefined
2016	0.03 undefined	-2.81 undefined	-2.77 undefined
2015	0.11 undefined	-3.17 undefined	-2.86 undefined
2014	3.26 undefined	1.08 undefined	0.6 undefined
2013	4.33 undefined	3.47 undefined	3.1 undefined
2012	2.28 undefined	1.21 undefined	1.08 undefined
2011	0.12 undefined	-0.49 undefined	-0.5 undefined

	주당 매출	EBIT 당 주식	주당 이익
2011	0.12 USD	-0.49 USD	-0.5 USD
2012	2.28 USD	1.21 USD	1.08 USD
2013	4.33 USD	3.47 USD	3.1 USD
2014	3.26 USD	1.08 USD	0.6 USD
2015	0.11 USD	-3.17 USD	-2.86 USD
2016	0.03 USD	-2.81 USD	-2.77 USD
2017	0.03 USD	-3.9 USD	-3.97 USD
2018	1.27 USD	-4.28 USD	-4.87 USD
2019	1.97 USD	-3.33 USD	-3.8 USD
2020	2.63 USD	-1.56 USD	-2.03 USD
2021e	3.33 USD	0 USD	-1.04 USD
2022e	4.44 USD	0 USD	-0.36 USD
2023e	4.77 USD	0 USD	-0.18 USD
2024e	5.63 USD	0 USD	-0.28 USD
2025e	6.78 USD	0 USD	-0.44 USD

	주식 수량
2011	16.43 백만 Aktien
2012	16.43 백만 Aktien
2013	16.43 백만 Aktien
2014	17.11 백만 Aktien
2015	18.11 백만 Aktien
2016	21.71 백만 Aktien
2017	22.56 백만 Aktien
2018	26.89 백만 Aktien
2019	27.68 백만 Aktien
2020	28.31 백만 Aktien
2021e	28.31 백만 Aktien
2022e	28.31 백만 Aktien
2023e	28.31 백만 Aktien
2024e	28.31 백만 Aktien
2025e	28.31 백만 Aktien

%-지분	이름	주식	변경
18.87544 %	Fidelity Management & Research Company LLC	5,449,340	176,940
16.00206 %	MDV Management Company, L.L.C.	4,619,796	0
13.85521 %	Armistice Capital LLC	4,000,000	144,000
13.56057 %	Stonepine Capital Management, LLC	3,914,938	1,220,643
10.84841 %	Magnetar Capital Partners LP	3,131,937	3,131,937
6.11372 %	The Vanguard Group, Inc.	1,765,031	13,211
5.14375 %	Swedbank Robur Fonder AB	1,485,000	0
5.05715 %	Opaleye Management Inc.	1,460,000	-210,600
3.98337 %	Point72 Asset Management, L.P.	1,150,000	-1,101,255
3.63389 %	Medical Strategy GmbH	1,049,103	0
2.77139 %	Cooper Creek Partners Management LLC	800,100	0
2.64362 %	Renaissance Technologies LLC	763,212	-19,600
2.43595 %	Two Sigma Investments, LP	703,258	-413,601
2.31225 %	MAI Capital Management, LLC	667,546	123,730
2.16650 %	Altium Capital Management LP	625,469	154,520
2.16515 %	Worth Venture Partners, LLC	625,080	34,350
2.02017 %	BlackRock Institutional Trust Company, N.A.	583,223	-13,551
1.82067 %	Acadian Asset Management LLC	525,628	-67,637
1.24953 %	Geode Capital Management, L.L.C.	360,738	25,632
1.23398 %	McFarlane (Neil F)	356,250	300,000
1.01638 %	D. E. Shaw & Co., L.P.	293,428	-175,432
0.99772 %	SilverArc Capital Management, LLC	288,042	-250,702
0.81795 %	BMO Capital Markets (US)	236,142	236,142
0.79559 %	BMO Asset Management U.S.	229,688	-12,702
0.68237 %	MacPhee (John A)	197,000	5,000
0.48493 %	DCF Advisers, LLC	140,000	0
0.39799 %	Bridgeway Capital Management, LLC	114,900	-150,000
0.39092 %	State Street Global Advisors (US)	112,859	9,700
0.39065 %	Mahoney (David L)	112,781	5,000
0.37485 %	Prentiss (Christopher B.)	108,219	72,578
0.34638 %	Healthcare Value Capital, LLC	100,000	0
0.34568 %	Shreedhar (Vishvanath)	99,797	-6,200
0.33907 %	Newton Investment Management North America, LLC	97,890	97,890
0.33061 %	Northern Trust Investments, Inc.	95,446	14,876
0.31629 %	Mosaic Family Wealth, LLC	91,314	0
0.25277 %	BlackRock Financial Management, Inc.	72,975	10,338
0.23900 %	Lieberburg (Ivan M)	69,000	5,000
0.23119 %	BofA Global Research (US)	66,745	6,406
0.21880 %	Principal Global Investors (Equity)	63,167	-474
0.20824 %	Morgan Stanley & Co. LLC	60,118	-6,115
0.15006 %	Apo Asset Management GmbH	43,322	0
0.13351 %	Susquehanna International Group, LLP	38,545	38,545
0.11802 %	SG Americas Securities, L.L.C.	34,073	-42
0.11614 %	Jacobs Levy Equity Management, Inc.	33,530	-17,173
0.10523 %	BNY Mellon Asset Management	30,381	0
0.10218 %	Campbell & Company, Inc.	29,500	29,500
0.09621 %	Citadel Advisors LLC	27,776	12,649
0.09468 %	Asset Management One Co., Ltd.	27,333	33
0.09006 %	T. Rowe Price Associates, Inc.	26,000	-7,700
0.08105 %	Zebra Capital Management, LLC	23,400	0
0.07341 %	HighVista Strategies LLC	21,193	6,437
0.07265 %	Papapetropoulos (Spyridon)	20,975	5,000
0.06923 %	Goldman Sachs Asset Management, L.P.	19,986	-3,765
0.06543 %	Clear Harbor Asset Management, LLC	18,889	-1,500
0.06517 %	Goldman Sachs & Company, Inc.	18,816	-21,489
0.06191 %	Charles Schwab Investment Management, Inc.	17,873	0
0.05709 %	Group One Trading, L.P.	16,483	16,483
0.05542 %	Dowling & Yahnke, LLC	16,000	0
0.05542 %	Demski (Martha J)	16,000	3,000
0.05520 %	Algert Global LLC	15,936	15,936
0.05196 %	Richo (Anna S.)	15,000	5,000
0.04662 %	Cubist Systematic Strategies, LLC	13,460	-900
0.04503 %	PNC Wealth Management	13,000	3,000
0.04337 %	Hightower Advisors, LLC	12,521	0
0.03907 %	Barclays Bank PLC	11,279	5,553
0.03879 %	United Bank, Inc.	11,200	11,200
0.03817 %	Nuveen Asset Management, LLC	11,020	0
0.03506 %	Capstone Investment Advisors, LLC	10,123	10,123
0.03182 %	BlackRock Japan Co., Ltd.	9,185	0
0.02840 %	Blackstone Alternative Investment Advisors LLC	8,200	0
0.02613 %	Northern Trust Global Investments	7,545	0
0.02600 %	BlackRock Investment Management, LLC	7,507	-803
0.02425 %	Morgan Stanley Smith Barney LLC	7,000	0
0.02212 %	BlackRock Investment Management (UK) Ltd.	6,386	0
0.02032 %	Mackenzie Financial Corporation	5,865	5,865
0.01732 %	Bigham (Michael F)	5,000	5,000
0.01732 %	Dier (Mardi C)	5,000	5,000
0.01732 %	Ericson (William)	5,000	5,000
0.01705 %	BlackRock Fund Advisors	4,923	4,923
0.01455 %	Advisor Group, Inc	4,200	-2,000
0.01239 %	Rockefeller Capital Management	3,576	0
0.00786 %	UBS Financial Services, Inc.	2,270	685
0.00381 %	Cutler Group, LP	1,100	0
0.00221 %	Truvestments Capital LLC	637	0
0.00104 %	Clearview Wealth Advisors LLC	300	0
0.00104 %	Wells Fargo Advisors	300	0
0.00077 %	Wells Fargo Bank, N.A.	221	-36
0.00069 %	RBC Capital Markets Wealth Management	200	0
0.00026 %	BNY Mellon Wealth Management	76	0
0.00016 %	Aperio Group, LLC	47	0
0.00010 %	J.P. Morgan Securities plc	28	0
0.00000 %	BNP Paribas Securities Corp. North America	1	0
0 %	Walleye Capital LLC	0	-16,700
0 %	AIGH Capital Management, LLC.	0	-2,585,743
0 %	Avidity Partners Management LP	0	-2,200,200
0 %	Maven Investment Partners US Ltd.	0	-250,000
0 %	XTX Markets LLC	0	-16,357
0 %	Jump Financial, LLC	0	-23,191
0 %	Voya Investment Management LLC	0	-40,980
0 %	Franklin Mutual Advisers, LLC	0	-1,243

What values and corporate philosophy does Adamas Pharmaceuticals represent?

Adamas Pharmaceuticals Inc represents a commitment to improving the lives of individuals living with chronic neurologic disorders. The company's corporate philosophy revolves around developing novel, targeted therapies that address unmet medical needs in areas such as Parkinson's disease and multiple sclerosis. Adamas Pharmaceuticals Inc aims to provide innovative treatment options that enhance patients' daily functioning and overall well-being. By leveraging their expertise in pharmacology and neurology, the company continues to prioritize scientific rigor, patient-centricity, and partnerships to drive advancements in the field. Adamas Pharmaceuticals Inc strives to make a positive impact on patient care through its dedication to research, innovation, and improving treatment outcomes.

In which countries and regions is Adamas Pharmaceuticals primarily present?

Adamas Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Adamas Pharmaceuticals achieved?

Adamas Pharmaceuticals Inc has achieved several significant milestones. One of the notable milestones is the FDA approval of their flagship product, GOCOVRI, in 2017. GOCOVRI is the first and only medication indicated for the treatment of dyskinesia in patients with Parkinson's disease. Another significant milestone for Adamas Pharmaceuticals Inc was the successful completion of their Phase 3 clinical trials for ADS-5102, a high-dose, extended-release formulation of amantadine. These milestones demonstrate the company's commitment to developing innovative therapies for neurological disorders and improving the lives of patients.

What is the history and background of the company Adamas Pharmaceuticals?

Adamas Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and delivering innovative therapies to address chronic disorders. Founded in 2000, Adamas Pharmaceuticals has a rich history of medical advancements and a deep commitment to improving patient lives. With a primary focus on central nervous system disorders, Adamas Pharmaceuticals diligently utilizes cutting-edge technology and scientific expertise to develop novel treatment options. Their notable breakthrough was the introduction of the FDA-approved medication, GOCOVRI, for the treatment of levodopa-induced dyskinesia in Parkinson's disease. With a strong emphasis on research and development, Adamas Pharmaceuticals Inc continues to pave the way for groundbreaking treatments in the medical field.

Who are the main competitors of Adamas Pharmaceuticals in the market?

The main competitors of Adamas Pharmaceuticals Inc in the market include companies such as Biogen Inc, Novartis AG, and Teva Pharmaceutical Industries Ltd. These companies operate in the pharmaceutical industry and may have similar products or focus on similar therapeutic areas as Adamas Pharmaceuticals Inc.

In which industries is Adamas Pharmaceuticals primarily active?

Adamas Pharmaceuticals Inc is primarily active in the healthcare industry.

What is the business model of Adamas Pharmaceuticals?

The business model of Adamas Pharmaceuticals Inc. revolves around developing and commercializing innovative therapeutics to address chronic diseases. Adamas focuses on improving patient outcomes through the discovery and development of novel treatment options. The company leverages its expertise in pharmacology, formulation, and drug delivery to create differentiated products. Adamas Pharmaceuticals Inc. strives to enhance the quality of life for patients by providing effective and accessible therapies. With a commitment to research and development, Adamas Pharmaceuticals Inc. aims to bring valuable treatments to market, thereby contributing to the advancement of healthcare.

Adamas Pharmaceuticals 2024의 P/E 비율은 얼마입니까?

Adamas Pharmaceuticals의 P/E 비율은 -29.22입니다.

Adamas Pharmaceuticals 2024의 KUV는 얼마입니까?

Adamas Pharmaceuticals의 P/S 비율은 1.43입니다.

Adamas Pharmaceuticals의 AlleAktien 품질 점수는 얼마인가요?

Adamas Pharmaceuticals에 대한 AlleAktien 품질 점수는 4/10입니다.

Adamas Pharmaceuticals 2024의 매출은 얼마인가요?

예상되는 Adamas Pharmaceuticals 매출은 162.49 백만 USD입니다.

Adamas Pharmaceuticals 2024의 이익은 얼마인가요?

예상되는 Adamas Pharmaceuticals 이익은 -7.96 백만 USD입니다.

Adamas Pharmaceuticals은 무엇을 하나요?

Adamas Pharmaceuticals Inc is a US-based company that specializes in the development and marketing of drugs for the treatment of neurological disorders. The company focuses on the treatment of Parkinson's disease and other movement disorders. Adamas has built its business on three pillars: - Product development - Product distribution - Technology licensing The company's key products are the medications GOCOVRI and NAMZARIC, both used for the treatment of Parkinson's disease. GOCOVRI is an extended-release and delayed-release version of the drug amantadine, while NAMZARIC is a combination of two drugs, cholinesterase inhibitors and memantine. GOCOVRI was developed to treat the symptoms of Parkinson's disease in the late phase when normal treatment methods such as dopamine agonists or levodopa are no longer successful. The medication was approved by the FDA in 2017 and is currently being marketed in the USA. Adamas Pharmaceuticals Inc has exclusive rights to GOCOVRI in the USA and Canada. NAMZARIC is another important product of Adamas Pharmaceuticals Inc. It is used for the treatment of moderate to severe dementia in patients with Alzheimer's disease. NAMZARIC contains two active ingredients - cholinesterase inhibitors and memantine - making it a unique medication. The medication was approved by the FDA in 2015. Adamas Pharmaceuticals Inc also has a strong presence in technology licensing. The company has an agreement with Forest Laboratories (now Allergan) for the licensing of intellectual property to manufacture Namenda, another medication for Alzheimer's disease. Adamas also has partnerships with other companies such as Osmotica Pharmaceuticals and Neurocrine Biosciences. The collaboration with these companies aims to create synergies and accelerate the development of new medications. The business model of Adamas Pharmaceuticals Inc is based on offering groundbreaking therapeutic solutions. The focus is on developing drugs for the treatment of central nervous system disorders and other neurological conditions. The company leverages its scientific knowledge and expertise to conduct clinical trials, develop innovative therapies, and establish connections with other partners. Overall, Adamas Pharmaceuticals Inc has developed an innovative and successful business model based on the creation of therapeutic solutions. The company has a strong presence in the neurological pharmaceutical industry and is expected to continue growing and thriving while continuing to develop innovative products to help improve patients' quality of life.